The role of de novo mutations in adult-onset neurodegenerative disorders by Nicolas G & Veltman JA
Vol.:(0123456789) 
Acta Neuropathologica 
https://doi.org/10.1007/s00401-018-1939-3
REVIEW
The role of de novo mutations in adult‑onset neurodegenerative 
disorders
Gaël Nicolas1,2  · Joris A. Veltman2,3
Received: 13 September 2018 / Revised: 14 November 2018 / Accepted: 14 November 2018 
© The Author(s) 2018
Abstract
The genetic underpinnings of the most common adult-onset neurodegenerative disorders (AOND) are complex in majority 
of the cases. In some families, however, the disease can be inherited in a Mendelian fashion as an autosomal-dominant trait. 
Next to that, patients carrying mutations in the same disease genes have been reported despite a negative family history. 
Although challenging to demonstrate due to the late onset of the disease in most cases, the occurrence of de novo mutations 
can explain this sporadic presentation, as demonstrated for severe neurodevelopmental disorders. Exome or genome sequenc-
ing of patient–parent trios allows a hypothesis-free study of the role of de novo mutations in AOND and the discovery of 
novel disease genes. Another hypothesis that may explain a proportion of sporadic AOND cases is the occurrence of a de 
novo mutation after the fertilization of the oocyte (post-zygotic mutation) or even as a late-somatic mutation, restricted to the 
brain. Such somatic mutation hypothesis, that can be tested with the use of novel sequencing technologies, is fully compatible 
with the seeding and spreading mechanisms of the pathological proteins identified in most of these disorders. We review here 
the current knowledge and future perspectives on de novo mutations in known and novel candidate genes identified in the 
most common AONDs such as Alzheimer’s disease, Parkinson’s disease, the frontotemporal lobar degeneration spectrum 
and Prion disorders. Also, we review the first lessons learned from recent genomic studies of control and diseased brains 
and the challenges which remain to be addressed.
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Introduction
The etiology of most of the adult-onset neurodegenerative 
disorders (AOND) is considered multifactorial, including 
genetic and environmental factors. In certain proportions of 
patients, the disease can, however, be inherited as a Mende-
lian trait, i.e., monogenic forms (Box 1). An autosomal-dom-
inant pattern of inheritance is the most frequently encoun-
tered, so that family history is often positive for the same 
disorder. Such monogenic forms may be associated with 
extreme phenotypes and early ages at onset, but this is not 
always the case. The existence of patients with an extreme/
early onset of AOND and a negative family history indi-
cates that this disease is not always transmitted in an auto-
somal-dominant fashion. Autosomal recessive inheritance 
explaining the disease in some of these patients has been 
described, for example, in patients with Parkinson’s disease 
[62], but in some patients, causal mutations were observed in 
autosomal-dominant genes known to cause AOND [62, 83, 
116, 168]. The primary hypothesis is that these mutations 
appeared in the germline of these probands as de novo muta-
tions (DNMs). To prove this, however, analysis of parental 
DNAs is required. As the disease onset even in these extreme 
cases occurs relatively late in life, one of the main practical 
challenges is access to parental biological samples [148].
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-018-1939-3) contains 
supplementary material, which is available to authorized users.
 * Gaël Nicolas 
 gaelnicolas@hotmail.com
1 Normandie Univ, UNIROUEN, Inserm U1245 and Rouen 
University Hospital, Department of Genetics and CNR-MAJ, 
Normandy Center for Genomic and Personalized Medicine, 
22, Boulevard Gambetta, 76000, 76031 Rouen Cedex, 
France
2 Department of Human Genetics, Radboud University 
Medical Center, Nijmegen, The Netherlands
3 Institute of Genetic Medicine, Newcastle University, 
Newcastle upon Tyne, UK
 Acta Neuropathologica
1 3
The advent of massive parallel sequencing (also called 
next-generation sequencing, NGS) has allowed researchers to 
assess the de novo paradigm in sporadic AOND in a genome-
wide manner using whole genome (WGS) or whole exome 
sequencing (WES). Sequencing of affected patients and their 
unaffected parents in a trio study design enables the identi-
fication of 1–2 DNMs per exome on average (for review see 
[3, [175] (Fig. 1a). This study design was originally applied 
to sporadic early-onset neurodevelopmental disorders and 
revealed a high genetic heterogeneity with many different 
genes affected by DNMs [42, 44, 69]. Although the applica-
tion of the trio study design to sporadic AOND is limited by 
the access to parental biological samples, recent successful 
applications were published on Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and amyotrophic lateral sclerosis 
(ALS) [37, 58, 84, 148, 162, 173].
Beyond germline mutations, there is now clear evidence 
that the human genome is mutable at any step of the devel-
opment and during the entire life (Fig. 1b). In AOND, a 
putative role for somatic DNMs is currently being assessed 
[105, 112, 152]. The mechanisms of seeding and spread-
ing of pathologic misfolded proteins are shared by multiple 
AONDs. It is thought to be a key mechanism explaining 
the irreversible progression of neurodegeneration through-
out the brain [126]. In theory, a small amount of pathologic 
seeds synthesized by a “colony” of neurons carrying a given 
somatic variant could be a source of spreading of a patho-
logical protein throughout the brain. The hypothesis that a 
putatively causal DNM could have happened after the fer-
tilization of the egg (post-zygotic mutation) or even later 
during the development (late-somatic mutation) has been 
evoked quite early in the recent history of human genetics 
[183]. However, it remained difficult to assess until recently, 
because of technological limitations. Novel sequencing tech-
nologies now enable researchers to address this question 
accurately.
In this review, we report and discuss the existing evidence 
of de novo germline mutations identified in the most com-
mon AONDs as well as the increasing interest in the search 
for post-zygotic variants as candidate causal mechanisms in 
some patients with a sporadic presentation.
Indirect arguments
The later a Mendelian disorder manifests in life, the more 
challenging it is to provide evidence of a de novo occur-
rence of causal mutations, because of reduced availability 
of parental samples. However, the late onset also has another 
effect: a significant difference between AOND and severe 
early-onset neurodevelopmental disorders—which have been 
shown to be largely caused by DNMs—is that AOND caus-
ing mutations do not affect the ability of the carriers to have 
children. Hence, pathogenic DNMs can be transmitted to the 
offspring. As with all genetic variants, mutations segregating 
in families arose de novo at a given date in a given individ-
ual. Hence, founder effects can be identified, and, eventually, 
it may be possible to date the original (de novo) mutation. A 
few of the recurrent mutations causing autosomal-dominant 
Alzheimer’s disease (AD) have been subjected to the study 
of a putative founder effect. The most famous one is cer-
tainly the Colombian PSEN1 p.E280A mutation. Identity-
by-descent analysis of the genomic sequence of 102 indi-
viduals originating from Antioquia provided the estimation 
of the DNM occurrence to 15 generations ago, back in the 
early 16th century [87]. Another well-known example is the 
Parkinson’s disease-associated p.G2019S LRRK2 mutation, 
which is known to be present on different haplotypes sug-
gesting different founders. One of them was estimated to 
have occurred 159 generations ago in a Berber founder [20]. 
The identification of recurrent mutations in autosomal-dom-
inant genes in the absence of a founder effect or evidence for 
multiple founders points to the regular occurrence of DNMs 
in these genes. For example, the PRNP p.P102L and the 
p.D178N mutations have been reported in multiple pedigrees 
on different haplotypes and indeed recently DNMs have been 
identified at these positions [81, 182] [8, 41]. Likewise, the 
recurrent SNCA p.A53T mutation has been shown to have 
occurred on different haplotypes as well as genuine de novo 
events [77, 134, 136]. In addition to point mutations, other 
genetic variations such as copy number variations (CNVs, 
genomic deletions or duplications) may also occur de novo. 
The existence of shared breakpoints mapping to short tan-
dem repeats on chromosome 21 among different families 
carrying diverse sizes of APP duplications indicates that 
multiple recurrent de novo duplications can cause mono-
genic forms of AD [149]. We can find similar evidence in 
synucleinopathies with SNCA copy gains (duplications and 
triplications) [147, 186].
Methods and strategies for the detection 
of de novo mutations in AOND
De novo mutations may occur in any cell. When a DNM 
occurs in a parent’s germ cell, it is present in the fertilized 
oocyte and hence in every cell of the individual born from 
the development of this oocyte (Fig. 1b). Detecting a ger-
mline DNM is therefore relatively easy, requiring just a lit-
tle bit of DNA from any tissue of the patient and his or her 
parents. Traditional and next-generation sequencing tech-
nologies allow the detection and validation of such mutation 
with a mutant: wild type allelic ratio of 1:1 (Table 1) in the 
patient, whereas the mutation should be absent in the DNA 
of both parents. In addition, it is important to check concord-
ance of the patient–parent trios through segregation analysis 
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Fig. 1  Germline, post-zygotic, and late-somatic de novo mutations: sta-
tistics, detection methods and their putative role in adult-onset neurode-
generative disorders. a Next-generation sequencing (NGS) consists of 
the massively parallel sequencing of short DNA fragments. This can be 
applied to the whole genome (WGS) or to targeted regions after the cap-
ture of regions of interest. For example, the capture of all coding regions 
allows the sequencing of the whole exome (WES). Whole genome 
sequencing (WGS) unveils around 4,000,000 variants (single nucleotide 
substitutions and short insertions and deletions) per individual genome. 
Among them, about 20,000 are located in the exons or canonical splice 
sites and hence detectable by WES. The trio study design consists of 
WGS or WES of a proband and his/her unaffected parents. After sub-
traction of all proband’s variants which were inherited from the parents, 
the variants that remain in the analysis are specific to the proband and 
are called de novo mutations (DNMs). WGS trio studies showed that 
about 60–80 high confidence DNMs can be identified per individual. 
Among them, 1.5 on average fall into the exome. b Among the DNMs 
identified per WGS of trios, about 7% have been shown to arise after 
the fertilization of the egg. These mutations are called post-zygotic or 
somatic mutations. During the entire life, every replicating cell can be 
affected by a novel mutation, giving rise to a colony of cells carrying 
this mutation. These mutations can arise lately in the development and 
during adult life, and possibly concern a single organ (late-somatic 
mutations). At most, a somatic mutation can concern a single cell. 
Although DNA replication is a main source of mutations in replicat-
ing cells, it has been shown that neurons, which are post-mitotic cells, 
can also be affected by novel, single cell mutations. These mutations are 
enriched in highly transcribed DNA regions, suggesting that neuronal 
activity can favor the occurrence of somatic mutations. DNMs can affect 
any genomic region. Hence, the nature of the biological consequence, 
if any, depends on the nature of both the region and the nucleotide 
change. While most of the DNMs do not have any significant biologi-
cal consequence and do not cause any disease, some can result in a rare 
monogenic disease or modify the risk of developing a given disorder. 
In adult-onset neurodegenerative diseases, pathogenic DNMs have been 
mostly identified in known autosomal-dominant genes, such as PSEN1 
in Alzheimer’s disease, FUS in amyotrophic lateral sclerosis, or PRNP 
in Prion disorders. The most compelling evidence comes from germline 
DNMs, identified either by targeted genetic screening or by WES. In 
addition, WES studies revealed DNMs in novel candidate genes, but 
their rarity does not yet allow the measurement of their contribution to 
the disease etiology in these patients
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to preclude false discovery of a DNM (e.g., false paternity). 
In AOND, the access to the parental samples remains an 
issue, limiting the detection of genuine DNMs. For these 
reasons, in a high proportion of the sporadic cases with a 
likely penetrant variation in a Mendelian gene, the evidence 
of the de novo occurrence could not be provided (e.g., [16, 
85]).
The use of WGS or WES with a trio study design allows 
the detection of DNMs in a hypothesis-free way. DNMs can 
be detected in any gene, opening the way to the discovery 
of novel causal genes. Every individual genome contains 
around 4.1–5.0 million SNVs or indels as compared to 
the reference genome, of them, 20,000 on average map to 
the exons and can hence be detected by WES [3]. Of these 
20,000 exonic or splice site variants, around 1000 are con-
sidered rare variants as they occur in less than 1% of the 
normal population. Sequencing a single exome or genome 
then faces the need to filter and prioritize these rare variants 
with the hypothesis that one of them could be causative. In 
sporadic diseases where the hypothesis that the cause could 
be a DNM, the bioinformatics subtraction of all variants 
identified in a proband that are also present in the parents 
(inherited variants) unveils the proband-specific variants, 
i.e., the DNMs [179]. On average, 40–80 DNMs can be 
identified per genome, of them 1–2 map to the exons ([3], 
Fig. 1a). This reduced number of candidate variants allows 
for a very effective follow-up in both research and diagnos-
tics. For these reasons, trio-based patient–parent studies are 
now routinely carried out in medical genetics. Sequencing 
dozens of patient–parent trios may often turn out to be more 
powerful than sequencing hundreds of simplex cases of spo-
radic disease.
In clinical practice, the inclusion of a trio for a WES in 
the context of an AOND requires that (1) the parents are 
unaffected (2) there is no further family history in other 
generations, to reduce the risk of alternative mechanisms 
such as variants with reduced penetrance, (3) the parents are 
clinically accessible. This latter point is mandatory, both for 
checking the absence of disease and for DNA sampling after 
informed consent. In diseases with an onset after 50 years, 
it can be basically challenging to recruit unaffected par-
ents with reduced mobility. Hence, only a small subset of 
patients and unaffected parents can be sampled, with a sig-
nificant effort and organization being required to recruit each 
trio. However, one can hypothesize that the development 
of genomic medicine will be associated with a dramatic 
increase in the number of individuals undergoing WES 
or WGS during their lifetime, contributing to the success 
of future trio studies. Similarly, the development of large 
nationwide biobanks such as the UK biobank may in the near 
future also be very helpful for retrieving the genomic data of 
parents from tomorrow’s patients.
When a DNM occurs after the fertilization of the oocyte, 
this mutation is considered a post-zygotic DNM. When these 
post-zygotic DNMs occur early in the embryonic develop-
ment, they may be present in majority of the individual’s 
cells, in tissues resulting from all three embryonic layers. 
Although post-zygotic and somatic mutations both refer to 
mutations being acquired during the lifespan of an individual 
[23], we will here use the term post-zygotic for mutations 
which have occurred during the early development, leading 
to their presence in most tissues from two or all three layers, 
and late-somatic mutations for those having been and being 
restricted to a single tissue, such as the brain. In addition, 
post-zygotic mutations may be transmitted to the offspring 
when present in the germline (germline or gonadal mosai-
cism) and explain how a germline heterozygous dominant 
de novo mutation may be present in affected sib pairs and 
Table 1  Main techniques for the detection of de novo mutations: pros and cons
DNM de novo mutation, NGS next-generation sequencing, WES whole exome sequencing, WGS whole genome sequencing
a Targeted, WES, or WGS. Note that the use of unique molecular identifier (UMI) may increase the accuracy of the variant calling for low-level 
mosaics by allowing the trimming of PCR duplicates and hence help distinguish true variants from PCR errors
Germline DNM Post-zygotic DNM
Sanger sequencing Restricted to a few genes Lack of sensitivity for mutations present in < 20% of cells
Targeted NGS (~ 100×) Restricted to selected genes
Can be analyzed affordably and at high throughput
Restricted to selected genes, but able to sequence many 
samples affordably
Detection of mutations possible if present in > 10% cells
Standard WES (50–100×) All coding regions, hypothesis free Detection of mutations possible if present in > 10% cells
Standard WGS (15–30×) All coding and non-coding regions, hypothesis free
Better sensitivity for structural variations
Relatively expensive
Detection of mutations possible if present in > 20% cells
Relatively expensive
Deep  NGSa Not much added value compared to standard depth NGS Increased sensitivity
Cost increasing with the number of genomic regions 
sequenced
Not affordable for WGS
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appear to be absent in the parents. A combination of ger-
mline and somatic mosaicism (gonosomal mosaicism) can 
have clinical consequences or not in the carrier [23, 32].
WES and WGS technologies are based on the multiple 
sequencing of every base by multiple short reads in a paired-
end sequencing manner, i.e., the sequencing of both extremi-
ties of a DNA fragment. The number of reads per position 
defines the depth of coverage. Most WES and WGS studies 
are performed with a depth of coverage allowing a high con-
fidence in the detection of germline homozygous (~ 100% of 
alternate reads) and heterozygous (~ 50%) variants. When 
the alternate: reference allelic balance is different from these 
expected ratios, the existence of a post-zygotic DNM can 
be suspected [1]. However, technical artifacts are the main 
source of such altered allelic balances, reducing the accuracy 
in the detection of post-zygotic variants. For these reasons, 
specific bioinformatics tools and independent molecular 
confirmations are required to confirm the presence of a 
post-zygotic variant instead of a sequencing artifact or a ger-
mline DNM. It has been shown that 6.5–7.5% of the DNMs 
detected in blood by WES actually occurred post-zygotically 
[1, 96]. The lower the true allelic ratio is, the more difficult it 
is to identify it reliably. Increasing the sequencing depth and 
the use of unique molecule identifiers (UMI, allowing the 
trimming of PCR errors) help to increase the confidence in 
low fraction post-zygotic or late-somatic mutations (Table 1) 
[3]. The technical aspects and implications of neuronal post-
zygotic mutations on aging have been recently reviewed 
[151, 177] as well as their putative role in neurodegenera-
tive diseases [94]. The sequencing of DNA isolated from the 
diseased tissue may help to identify late-somatic DNMs. In 
AOND, the access to CNS tissue is highly limited in vivo. 
Studies focusing on late-somatic DNMs must therefore rely 
on autopsies of patients, including the input of brain banks. 
For multiple reasons, despite the development of such brain 
banks in many Western countries, the proportion of patients 
undergoing full autopsy remains very low, limiting the use of 
such facilities. In addition, it becomes clear that brain banks 
should store not only brain tissue but also other tissues, to 
allow a better characterization of post-zygotic events.
In addition to the detection of putatively causal post-
zygotic mutations, the same technologies can also be used to 
search for (1) “back mutations” that reverse or partially cor-
rect a phenotype or (2) second-hit mutations that trigger the 
disease in the presence of an additional inherited germline 
mutation. Although examples of both mechanisms have been 
described in other diseases such as skin diseases [124, 125], 
cortical dysplasia [140] or the neurocutaneous disorder neu-
rofibromatosis type 1 [157], we could not find any example 
in AOND. It could be that these mechanisms play a more 
prominent role in rapidly dividing cells. Of note, the exist-
ence of an inherited genetic variant protecting against Prion 
infection seems to be in line with this theoretical hypothesis 
[12]. In addition, we cannot exclude a two-hit mechanism in 
certain diseases. Of note, in the FTLD–ALS spectrum, sev-
eral genes share common mechanisms of RNA metabolism 
perturbation [133]. One could expect that second-hit post-
zygotic mutations in the same pathways may increase such 
pathogenic processes. This would even be consistent with 
the hypothesis of a multistep process for the development of 
ALS [5]. Likewise, in AD, any post-zygotic second mutation 
that would modify the production, aggregation, toxicity or 
clearance of the Aβ peptide could in theory influence the 
disease progression [33].
De novo mutations in known 
autosomal‑dominant genes
Chromosomes and copy number variations
The major prevalence of Alzheimer’s disease and the pres-
ence of amyloid pathology observed very early in the life of 
patients with Down syndrome [55] suggested that an extra 
copy of the chromosome 21 might be sufficient to cause 
the disease. The identification of duplications of the APP 
locus (mapping to the chromosome 21) causing autosomal-
dominant EOAD (early-onset Alzheimer’s disease, onset 
before 65 years) without Down syndrome [149] was of 
major importance to confirm the amyloid hypothesis stat-
ing that the Aβ peptide aggregation, produced following the 
processing of the APP protein, has a key role in AD patho-
physiology. As most trisomy 21 cases occur de novo, it can 
be considered as the most common cause of DNM causing 
sporadic AD, although occurring in patients with a genomic 
disorder. The first de novo duplication of the APP locus, 
not encompassing the critical Down syndrome region, has 
been recently reported in a patient with neuropathologically 
confirmed sporadic EOAD [148].
The study of CNVs in AD has been performed with 
genome-wide screens by array CGH or SNP arrays in 
patients with or without a family history [65, 150]. For 
example, an array CGH screen performed in patients with 
EOAD identified a few candidate CNVs, some of which 
were identified in sporadic EOAD patients. Unfortunately, 
segregation of these CNVs could not be assessed in parents 
[150]. More recently, a de novo partial deletion of intron 1 
of the BACE2 gene was identified in a patient with sporadic 
EOAD [148]. It has been hypothesized that this deletion 
of highly conserved non-coding genic DNA could lead to 
decreased non-amyloidogenic processing of APP, but the 
functional consequences remain to be determined. In a WES 
study of 522 EOAD cases including familial and sporadic 
cases and 584 controls, a 17q21.31 duplication encompass-
ing the MAPT gene encoding the Tau protein was identified 
in 4 probands [92]. In one of them, the duplication occurred 
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de novo and the parents were indeed unaffected by any neu-
rodegenerative disease. This observation, together with the 
segregation of the same duplication in one family with an 
EOAD clinical presentation and the absence in controls, 
was a strong argument suggesting causality. Interestingly, 
although the patients were selected for an accurate diagnosis 
of EOAD with clinico-biological arguments, this duplica-
tion may eventually cause a novel primary tauopathy, closely 
linked but neuropathologically distinct from AD.
Overall and despite the major role of CNVs in human 
genetics, only a few examples are known to cause autoso-
mal-dominant AOND. Of them, duplications or triplications 
of the SNCA gene have been identified in families with Par-
kinson’s disease or Lewy body dementia. In three unre-
lated patients with Parkinson’s disease, increased dosage of 
the SNCA gene was identified as a DNM (Supplementary 
Table 4) [127, 128], present in 42–75% of oral mucosa cells 
of these patients, and absent or present at very low percent-
ages in blood, indicating post-zygotic occurrence. However, 
given the complexity of distinguishing post-zygotic muta-
tions from technical artifacts, it remains important to con-
firm these findings by independent technological approaches 
(see also below).
De novo point mutations: an earlier age of onset 
is associated with an increased DNM detection rate
Genetic analysis of sporadic patients presenting either an 
early-onset AD or a late onset of AD (the most common 
form) has been performed since the identification of the first 
causative genes (e.g., [40, 155, 185] or even before, as a 
candidate gene [180], but most of them were negative. The 
first proven DNM in AD was a PSEN1 pathogenic mutation 
identified in the blood of a patient with a disease onset at 
the age of 37 years, reported in the context of a screening 
of 13 sporadic AD patients with a very early onset (before 
51 years) [48]. Later on, two novel cases of PSEN1 DNMs 
were reported [56, 130] so that more than 10 years after the 
identification of the three known causal AOND genes APP, 
PSEN1 and PSEN2, only three pathogenic DNMs had been 
published (Table 1).
Recently, the genetic screen performed on blood samples 
of 129 sporadic patients with a very early age of onset (< 51 
years) revealed a mutation detection rate of 14% (18/129) 
in the three known causal genes [88] (Fig. 2). Among them, 
the pedigrees of six showed a censoring effect (meaning 
that at least one parent died early, before the putative onset), 
parental DNA was not available although no censoring effect 
was noticed for nine, and parental DNA was available in ten 
cases, demonstrating the de novo occurrence of the muta-
tion in each proband. Another screen performed by WES in 
174 patients with sporadic EOAD starting between 51 and 
65 years showed a much lower mutation detection rate of 
1.2% in these genes (parental DNA not available, [116]). 
Taken together, this suggests that an earlier age of onset 
is a good predictor of a pathogenic variant in one of these 
genes and that such variants have a high probability to have 
occurred de novo (Fig. 2).
In addition to these ten aforementioned DNMs [88, 148], 
two additional PSEN1 DNMs have been published [35, 99], 
as well as one post-zygotic PSEN1 DNM [18] adding up to 
a total of only 14 DNMs ever reported as causing EOAD, 
all but one in PSEN1 (Table 2, Supplementary Table 1). The 
only PSEN1 post-zygotic DNM was identified in a woman 
with estimated degrees of mosaicism in blood and cerebral 
cortex of 8% and 14%, respectively [18]. She transmitted 
the mutation to her daughter, showing that the mutation 
encompassed gonadal cells. Notably, the mother presented 
a dementia onset at 52 years together with Parkinsonism 
and mild spastic paraparesis, whereas the affected daughter 
already presented the first symptoms of neurodegeneration 
at the age of 27, associated with dementia, cerebellar ataxia 
and spastic paraparesis. As this is a single family observa-
tion, it is unclear whether this difference in disease onset can 
be due to the germline vs. mosaic presence of the mutation 
(Table 2, Supplementary Table 1).
Similar to AD, the percentage of patients with pathogenic 
DNMs also seems to be highly correlated with the age at 
onset in other AONDs. For example, a frequency of 1% FUS 
mutation carriers was found among 500 cases with sporadic 
ALS (mean age at onset: 60 years), including one DNM in 
the blood of a patient with an onset at 36 years [167], but 
higher FUS mutation detection rates were reported when 
screening series of younger sporadic patients, as for exam-
ple, 3/11 (27%) [188] and 6/14 (43%) [67] in patients with 
an age of onset of less than 25 and 35 years, respectively. 
The FUS gene is the most recurrently hit gene by DNMs in 
sporadic ALS with 9 different DNMs reported in 18 inde-
pendent cases (Table 3 Supplementary Table 2) [4, 17, 31, 
38, 39, 45, 66, 67, 78, 93, 167, 188], compared to only one 
in SOD1 [7], one in VCP [13], one in the novel gene ERRB4 
[166] and two in the MAPT gene in the FTLD spectrum 
[25, 117], including one shared by two siblings indicating a 
mosaic DNM encompassing the germline in one parent [25].
Despite the difficulty to assess the de novo occurrence 
of a pathogenic mutation detected in a Mendelian gene in 
a patient with a sporadic AOND, we found a total of 49 
published examples (Table 3, supplementary Tables 1–4). 
The vast majority of them was reported in recent years, with 
18 out of the 29 DNMs (62%) hitting “old” genes (APP, 
PSEN1, PSEN2, MAPT, SNCA, PRNP, SOD1) having been 
reported in the 2010s. This highlights an increasing interest 
in sporadic AOND genetics, but it also indicates that novel 
sequencing approaches and the trio-based study design are 
successfully being used. The highest numbers of proven 
DNM have been identified in sporadic early-onset ALS, 
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especially in the FUS gene (all with a disease onset before 
40 years). ALS is associated with a short life expectancy 
following the diagnosis and young patients often present 
with highly penetrant variants. This may have facilitated the 
prioritization of pathogenic variants as well as the collection 
of parental samples for demonstrating de novo occurrence. 
Similarly, all patients with a proven DNM in a known Men-
delian AD gene had a disease onset before 50 years (range: 
23–47 years). This may lead us to think that DNMs mainly 
cause early-onset sporadic AOND. This observation, how-
ever, is impacted by the fact that it is almost impossible 
to assess the role of DNMs in late-onset patients, because 
parental DNA samples will mostly be unavailable. The low 
mutation detection rates of known AOND causative genes 
in older sporadic patients do, however, suggest that this is 
not the only factor. It is well-known that early-onset severe 
disorders are more often monogenic and de novo in origin, 
whereas late-onset diseases show more complex inheritance 
[175].
Recurrence of DNMs
Among the AOND genes affected by DNMs, PSEN1 (AD), 
FUS (ALS) and PRNP (Prion disorders) are mostly reported 
(Table 2). Of the 11 missense PSEN1 DNMs reported, 8 
mapped to genomic positions already identified by another or 
the same causative mutation in families, and two additional 
ones mapped to a same codon. Three DNMs in FUS were 
identified as recurrent DNMs: one missense (c.1574C > T, 
p.Pro525Leu in 8 patients) and two protein-truncating muta-
tions (one nonsense and one frameshift indel, each observed 
twice as DNMs). Interestingly, four additional FUS DNMs 
Fig. 2  Mutation detection rates in autosomal-dominant genes: the 
example of early-onset Alzheimer disease. In sporadic patients with 
the earliest ages of onset, the mutation detection rate was higher than 
in patients with later ages of onset. This rate was mostly related to de 
novo mutations. When ages of onset are later, the proportion of inher-
ited variants with reduced penetrance may increase. Note that  the 
majority of these presentations may be non-Mendelian (complex 
determinism), whatever the age of onset. In familial presentations, 
the mutation detection rates were the highest when the family history 
suggested an autosomal-dominant transmission of EOAD (at least 
two generations with EOAD). In other cases (proband with EOAD, 
positive family history of Alzheimer disease with an onset after 65), 
the mutation detection rates are very low. In these forms too, a com-
plex determinism is the most likely hypothesis. The mutation detec-
tion rates concern the three autosomal-dominant genes APP, PSEN1, 
and PSEN2. a Lanoiselee et al. [88] Plos Medicine 2017. b Nicolas 
et  al. [116] European Journal of Human Genetics 2016. c Wallon 
et al. [181] Journal of Alzheimer’s Disease 2012
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affected genomic positions where the same change had 
been reported as pathogenic in sporadic cases or families. 
Although no parental data was available for those cases, it 
still does indicate that these positions are affected by recur-
rent DNMs. In addition, two FUS DNMs are also present 
in the gnomAD database consisting of genetic variations 
identified in controls free of severe pediatric disease, with 
a maximum allele count of 5 (out of ~ 138,000 individuals) 
[95]. One of these was the recurrent nonsense DNM. This 
suggests that, although cases with a DNM in FUS were all 
young, the mutations may not be fully penetrant in other 
genomic contexts. Of the six reported PRNP DNMs, includ-
ing one possibly post-zygotic mutation [8], all were reported 
in additional independent cases or families [34, 41, 63, 81, 
154]. This may suggest the existence of hotspots or recur-
rent mechanisms such as octapeptide repeat expansions in 
the Prion gene.
Interestingly, no APP or PSEN2 SNV has ever been 
reported as occurring de novo in a patient with AD. There 
is no evidence of a higher mutability of the PSEN1 gene as 
a whole [95, 153]. However, PSEN1 pathogenic variants are 
more frequent in autosomal-dominant families and PSEN1 
mutation carriers exhibit an earlier age at onset on average, 
compared to the other genes [88, 181]. This may help physi-
cians to get access to parental samples at the time of their 
child’s diagnosis and introduce a bias in this analysis.
Repeat expansions
There are multiple examples of neurological disorders 
caused by repeat expansions. Intra-familial instabil-
ity of such repeats has been identified in diseases such as 
Friedreich’s ataxia, DRPLA or Huntington’s disease (for 
review, see [129]). Such instability is a particular form of a 
DNM that can lead to anticipation of the age of onset with a 
few dramatic examples [61]. In the main AOND, GGG GCC 
repeat expansions in the C9ORF72 gene are also subject 
both to intra-familial and somatic instability [53, 164]. How-
ever, the ranges of repeat sizes conferring instability that can 
be translated to a pathogenic expansion in the offspring or in 
other cells of the body remain to be identified. By analyzing 
blood and CNS samples of patients with ALS, it has been 
suggested that such instability is not likely to be of suffi-
cient magnitude to result in a pathogenic expansion in the 
CNS from a normal C9ORF72 repeat length in blood [120]. 
Similarly, ATXN2 intermediate repeat expansions have been 
shown to increase the risk of FTLD–ALS and have been 
reported as somatically instable [86, 111, 174].
Monogenic causes in sporadic patients: alternative 
hypotheses
Beyond the possibility of a DNM hitting a gene with an 
autosomal-dominant pattern of inheritance, several alterna-
tive hypotheses remain consistent with a monogenic cause 
for sporadic AOND patients. Most obviously, several forms 
of sporadic early-onset Parkinson’s disease (PD) cases are 
related to autosomal recessive inheritance—with early and 
possibly clinically distinct clinical presentation—as is the 
case for a few examples in FTLD–ALS or related, sometimes 
clinically undistinguishable disorders [22]. In addition, in 
PD, the identification of an inherited pathogenic mutation 
in a dominant gene in a sporadic case is not uncommon [83]. 
Although some of the presentations are clinically distinct 
Table 2  Summary statistics of causal de novo mutations reported in known autosomal-dominant genes of the most frequent adult-onset neurode-
generative disorders
DNM de novo mutation, FTLD frontotemporal lobar degeneration, ALS amyotrophic lateral sclerosis
a All are increased copy numbers
Nosological spectrum Gene Number of germline DNM Number of post-
zygotic DNM
Age of onset 
(average, range)
List of mutations and references
Alzheimer’s disease PSEN1 13 1 35.9 [23–52] Supplementary Table 1
APP (duplication) 1 0 44 Supplementary Table 1
FTLD–ALS spectrum FUS 18 (ALS) 0 22.3 [11–36] Supplementary Table 2
MAPT 4
(PSP, n = 1; bvFTD,  n = 2; 
EOAD-like:  n =  1)
0 39.25 [30–46] Supplementary Table 2
SOD1 1 (ALS) 0 20 Supplementary Table 2
VCP 1 (ALS) 0 36 Supplementary Table 2
ERBB4 1 (ALS) 0 45 Supplementary Table 2
Prion disorders PRNP 5 1 28.25 [18–34] Supplementary Table 3
Synucleinopathies 
(Parkinson’s disease)
SNCA 1 3a 26.5 [18–35] Supplementary Table 4
Total 44 5 29.6 [11–52 ] Supplementary Tables 1-4
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including an early onset, reduced penetrance has been iden-
tified for a subset of the genes and pathogenic mutations. 
We could find only one detailed report of a likely DNM 
in a known autosomal-dominant PD gene [136] (Supple-
mentary Table 4). Hence, sporadic presentations may be 
more frequently due to autosomal recessive inheritance or 
autosomal-dominant inherited mutations with reduced pen-
etrance rather than DNM in PD, aside from complex forms. 
Although autosomal recessive inheritance is not uncommon 
for known Parkinson’s disease genes, it remains unclear if 
this will also be the case for the remainder of causal genes 
to be discovered. A recently published WES study indicated 
that this may not be the case [71]. Similarly, the patho-
genic C9ORF72 repeat expansion causing FTLD–ALS was 
reported in 5% of sporadic cases [168] and may be much 
more frequently inherited from an asymptomatic parent than 
occurring de novo [108]. In AD, a few mutations have also 
been reported as associated with reduced penetrance (e.g., 
APP p.A713T, PSEN1 p.A79V [88]) and only one mutation 
in APP is considered causing AD in a homozygous state 
[47].
Of note, in addition to autosomal-dominant variants with 
reduced penetrance and autosomal recessive inheritance, 
sporadic occurrence might also be related to di-, oligogenic 
or a more complex inheritance. Some AOND such as AD 
and ALS exhibit a high heritability as measured by compar-
ing concordant and discordant monozygotic and dizygotic 
twin pairs (58–79% depending on the models for AD [52] 
and 38–74% in ALS [6]), whereas this was more modest 
in Parkinson’s disease (34%) [184]. In FTLD, it has been 
estimated that in most of the cases, frontotemporal demen-
tia would be a genetic-based disease, even late-onset cases 
[26]. The inheritance patterns may be more complex in 
some instances, as suggested by the observation of dam-
aging TBK1 as well as OPTN mutations in a patient with 
FTLD-TDP [132]. In AD, the high odds ratios of risk fac-
tors such as the common APOE4-4 genotype or rare vari-
ants in TREM2, SORL1 or ABCA7 in EOAD (for review, 
see [113]) suggest that they contribute significantly to the 
genetic component of EOAD in a complex determinism, 
including sporadic and familial presentations. Likewise, in 
Parkinson disease, high odds ratios associated to heterozy-
gous GBA variants suggested oligogenic inheritance in some 
cases [100]. Although a complex etiology might be relevant 
for a certain proportion of patients with sporadic AOND, it 
remains difficult to predict which patients, based on clinical 
criteria.
Looking for novel genes hit by de novo 
mutations: whole exome sequencing of trios
The evidence that highly penetrant mutations can arise de 
novo in known Mendelian genes was a proof of concept 
allowing the assessment of the de novo paradigm at the 
scale of the entire exome, looking for novel genes. As for the 
known autosomal-dominant genes, applying the trio study 
design requires the access to parental biological samples. To 
date, six trio studies have been published: one in AD, three 
in ALS, and two in PD, with a total of 247 trios included 
(Table 3).
Sporadic early‑onset AD: enrichment of DNM 
in the Aβ network and in vitro characterization
After blood sampling of 14 patients with EOAD (mean age 
at onset: 50 years) and their unaffected parents and CNV 
screen by array CGH, WES of the 12 trios with no de novo 
CNV revealed 12 de novo non-synonymous variants in 6 
patients, including one of the above-mentioned PSEN1 
DNMs [148] (Table 3). A significant enrichment of non-syn-
onymous DNMs was found in a network of genes centered 
on the Aβ peptide. Of particular interest, two novel genes 
affected by DNMs were further studied: VPS35 and MARK4. 
In silico and in vitro studies showed a deleterious effect of 
these DNMs with functional results being totally in line with 
AD pathophysiology. The VPS35 missense DNM was shown 
to result in reduced protein function and hence predicted to 
result in increased Aβ secretion. This mutation had strik-
ing different functional consequences than the previously 
reported Parkinson disease-causing VPS35 variant, even 
though both affected amino acids are located close to each 
other in the protein sequence [148, 178, 187]. The MARK4 
variant increased the phosphorylation of Tau in a key posi-
tion for Aβ-mediated toxicity. The trio strategy pointed here 
two novel genes, not previously related to AD genetics but 
whose gene products are key players in AD pathophysiol-
ogy. One can hypothesize that they contributed significantly 
to the development of the disease in their carriers, but their 
penetrance cannot be assessed without segregation data in 
the offspring of the carriers or recurrence in unrelated indi-
viduals, currently limiting the impact for genetic counseling.
Two independent studies in ALS reveal one 
recurrently hit gene and pathway enrichment
In sporadic ALS, three trio studies using WES performed 
from blood samples were published. A first study reported 
47 trios (mean age at onset: 32.1 years) and identified 25 
genes hit by non-synonymous DNMs [37] (Table 3). After 
functional annotation, a significant enrichment in genes 
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encoding chromatin regulators was found (5/25), including 
the neuronal chromatin remodeling complex component 
SS18L1 (also known as CREST). In a replication sample 
of 62 WES of families with ALS, a novel missense SS18L1 
mutation was found in a proband. Both mutations inhibited 
activity-dependent neurite outgrowth in primary neurons, 
and CREST protein was associated with FUS in neurons. 
In an independent screen of SS18L1 in 87 patients with 
familial ALS, two novel mutations were identified in unre-
lated probands [169], although one latter patient also pre-
sented a potential pathogenic mutation in the OPTN gene (a 
gene associated with recessive or dominant FTLD–ALS). 
Although the role of SS18L1 and other genes hit by DNMs 
in this first WES study remains to determined, this study 
design unveiled good candidate genes to be studied further.
The second study enrolled 44 trios for WES (mean age 
at onset: 46.1 years) including one patient with FTLD–ALS 
(Table 3) [162]. Importantly, patients carrying pathogenic 
mutations in known genes were not excluded, as two carried 
a C9ORF72 repeat expansion, one a SOD1 mutation and one 
a TARDBP mutation; these mutations were inherited from 
an asymptomatic parent. Of 54 DNMs identified, 17 non-
synonymous or canonical splice site mutations were found 
in 12 trios (or 15 mutations in 11 trios after excluding a trio 
carrying a C9ORF72 repeat expansion with two non-syn-
onymous mutations, [162]). Taking into account both WES 
trio studies together, one gene, CHRM1, was hit more than 
once, by a novel missense [37] and a start loss DNM [162]. 
While very exciting, the interpretation of the role of CHRM1 
DNMs in ALS pathophysiology remains to be assessed by 
functional analyses. In a similar in silico functional enrich-
ment analysis using the DAVID bioinformatics tool as in the 
first study, the genes related to transcription regulation were 
highlighted as enriched in DNMs [162]. These first two trio 
studies performed on sporadic ALS highlighted the genetic 
heterogeneity and the need to analyze multiple trios at the 
same time or in the context of meta-analyses.
Recently, 82 additional sporadic ALS trios were reported 
(WES, n = 61; WGS, n = 21) [173]. No additional recur-
rence was identified at the gene level. The interpretation 
of results was conflicting with previous reports as global 
analysis of all genes hit by non-synonymous DNMs among 
the 173 published trios did not reveal any enrichment in the 
previously identified categories of genes (chromatin regula-
tors, transcription regulation). Instead, an enrichment in the 
phosphoproteins category was identified, and no increased 
protein–protein interactions were identified as compared to 
the known interactions among known genes.
Protein–protein interaction and recurrence 
of variants in large cohorts of Parkinson disease 
patients
One WES study was performed on 21 trios of early-onset 
PD (onset before 40 years) [84] (Table 3). Twenty DNMs 
(19 non-synonymous) were identified for which in silico 
functional gene annotation and protein–protein interaction 
analyses were performed using the STRING bioinformatics 
tool. Three genes showed significant interactions with the 
known PD genes: PTEN, VABP, and ASNA1. Additional rare 
variants were identified from exome data of more than 1200 
cases from the International Parkinson’s Disease Genom-
ics Consortium (IPDGC). Although functional pathways 
link PTEN to PD pathophysiology, the putative role of the 
DNMs found in patients with PD remains to be elucidated. 
In particular, the DNM identified in the replication sample is 
predicted to result in a loss of function and hence supposed 
to cause Cowden syndrome. In addition, while this variant 
occurred de novo, the proband’s father was also affected with 
PD, showing non-co-segregation. VAPB missense mutations 
have been previously shown to cause autosomal-dominant 
ALS. The patient identified in the PD trio study presented 
an unknown in-frame deletion of one residue and two addi-
tional cases from the IPDGC dataset presented rare coding 
mutations in the same domain as the one reported to carry 
ALS-causative mutations. Whether or not these mutations 
have a functional effect and are related to PD pathophysiol-
ogy remains to be determined.
Very recently, a trio-based WES study reported 39 early-
onset PD patients of Han Chinese origin [58]. After pri-
oritization of DNMs based on protein–protein interactions 
and expression profiles in the brain, 12 genes were selected 
for case–control sequencing analyses. Among them, NUS1, 
which showed a splicing DNM in a proband, was enriched 
in non-synonymous rare variants with an OR of 11.3 and a 
p value approaching exome-wide significance (1.02  10−5) 
among 5089 cases and 4423 controls. In addition, a Dros-
ophila model expressing an siRNA against the fly NUS1 
orthologue showed decreased climbing ability, a reduction in 
dopaminergic neurons and a dramatic reduction in the brain 
dopamine levels. Of note, all coding variants identified in 
the replication case–control analysis were missense and their 
inheritance was unknown, but the DNM mutation introduced 
a splicing defect resulting in the frameshift deletion of 91 bp 
of exon 3. This could suggest a haploinsufficient mechanism. 
However, protein-truncating NUS1 DNMs have previously 
been reported in patients with global developmental delay 
and seizures [60], two of them also had a tremor. In addi-
tion, a 6q22.1 microdeletion, the critical region of which 
encompassed this gene, has been identified in patients with 
early-onset seizures [165] and a homozygous missense vari-
ant resulting in a protein loss of function was reported in 
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two siblings with a congenital glycosylation disorder [123]. 
Given the very early onset of neurological signs in the 
NUS1 DNM carrier in the PD study (16 years), the in-depth 
phenotypic description of patients carrying DNM will be 
of interest to better characterize the clinical expression of 
these mutations, in addition to the replication in other WES 
studies.
WES of trios in AOND: validation warranted
We found six trio studies applied to sporadic AOND 
(Table 3), all with limited samples sizes: one in AD (14 
trios), three in ALS (total of 173 trios), and two in PD (total 
of 60 trios). Yet, the power of these strategies allowed the 
identification of at least two novel genes in EOAD genetics 
with a demonstrated functional effect (VPS35 and MARK4) 
[148], one in ALS (SS18L1) [37], and one recently in PD 
(NUS1) [58]. Other variants, affecting genes not yet known 
to be involved in the Aβ network in AD, or the recurrently 
hit gene CHRM1 in ALS, might also be confirmed as truly 
involved in further studies.
Although the extreme resolution of the trio study design 
makes it a choice strategy in extreme presentations of spo-
radic AOND with no pathogenic variant in known genes, the 
identification of a DNM in a patient with a sporadic AOND 
is not sufficient to confirm its role in the disease etiology. 
Validations are mandatory to confirm the involvement of a 
novel gene identification through this process. Several strate-
gies can be proposed: (1) functional assessment of variants, 
(2) recurrence in independent cases, (3) variant enrichment 
in case–control studies.
1. Functional assessment of the impact of DNMs relies on 
the previous knowledge on the disease pathophysiology 
and mutated genes. It was possible to assess the role 
of VPS35 and MARK4 mutations mostly because the 
function of their gene products was well-documented 
and because AD pathophysiological pathways, although 
diverse, can all be linked to the amyloid cascade hypoth-
esis [33]. Regarding the SS18L1 gene, the known expres-
sion in motor neurons was a strong argument to justify 
its assessment, although the effects of the observed 
mutations might not be specific to ALS pathophysiol-
ogy. In PD, although a direct functional link between 
NUS1 and PD was not known, a use of a clear biological 
read out in the Drosophila model (dopaminergic impair-
ment) pointed to the relevance of this gene [58]. It is, 
however, very challenging to perform a systematic func-
tional assessment on all DNMs identified in a WES trio 
study and therefore in most cases only strong candidates 
are selected for functional validation.
2. The argument of recurrence, at the variant or at the gene 
level, in patients with the same phenotype, is a key argu-
ment in human genetics. A good example of this is the 
observation of recurrent DNMs in the CHRM1 gene in 
ALS by the combination of the first two studies. How-
ever, it is important to assess the a priori probability of 
a gene to be hit by multiple DNMs by chance, because 
the DNM rate varies per gene, depending on character-
istics such as the gene size and the GC content [153]. 
The statistical rigor required to demonstrate a significant 
enrichment of DNMs in a gene may require the analysis 
of many hundreds to even thousands of trios [43], which 
seems unrealistic in AOND. As discussed before, how-
ever, most of the AONDs are compatible with parent-
hood. As for PSEN1, APP, or FUS mutations, for exam-
ple, one could expect to find pathogenic mutations in 
novel genes such as VPS35, MARK4, SS18L1, CHRM1 
segregating in families if these mutations are highly pen-
etrant. It may therefore be useful to perform replication 
studies in large cohorts, whether or not the patients pre-
sent a positive or a negative family history, as performed 
in PD and ALS studies [37, 58, 84]. However, without 
sufficient segregation data as in the above-mentioned 
examples, no conclusion can be drawn.
3. The recurrence of rare variants at the gene level can also 
be assessed by association analysis in a case–control set-
ting, as successfully applied for NUS1 rare variants in 
PD [58]. WES or WGS data are rapidly increasing in 
terms of sample sizes, allowing for powerful associa-
tion studies of rare variants. For example, about 5000 
late-onset AD cases and 5000 controls have been exome 
sequenced by the US governmental AD Sequencing 
project (ADSP, [24]) and WES of 1779 AD cases and 
1273 controls have been included in association studies 
in France [19]. So far, genes affected by DNMs in trio 
studies have not been reported to be significantly associ-
ated with AD in these association studies. Notably, the 
major roles of TREM2, SORL1 and ABCA7 rare variants 
have been highlighted in AD [19, 73, 91, 114, 163]. As 
expected, an apparent inverse correlation was identi-
fied between the effect size at the gene level (measured 
by the odds ratios, OR) and the cumulative frequency 
of the variants in controls: the genes with the highest 
OR (TREM2 > SORL1 > ABCA7) were hit by damag-
ing variants in the inverse order in terms of cumulative 
frequency [19]. This observation, added to the full pen-
etrance of autosomal-dominant pathogenic variants that 
are extremely rare in controls, is compatible with the 
paradigm reported by Manolio et al. [101] and McCa-
rthy et al. [102] suggesting such inverse correlation for 
most of the association signals which can be detected 
using current methods. If DNMs identified in trio-based 
studies eventually carry a strong effect, they are likely to 
be extremely rare, so that association studies might fail 
in reaching the 2.5  10−6 p value threshold required for 
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exome-wide significance. Conversely, their extreme rar-
ity is not sufficient to postulate on penetrance. The trio 
study design having an individual resolution, it remains 
possible that mutations in novel genes might be present 
only in a very limited number of cases in the world, 
precluding any confirmation by identifying recurrences 
leading to a significant association signal.
Lacking gene level evidence for most of the genes, WES/
WGS trio studies attempted to find enrichment of DNMs at 
a larger scale by grouping genes into networks or pathways. 
Although this approach adds evidence to the study model, it 
does not allow the investigators to draw conclusions about 
the role of individual genes. Even in cases of a demonstrated 
functional effect, no genetic counseling can be provided to 
the carriers’ offspring and to putative unrelated carriers of 
rare variants in these genes.
Overall, when large series of patients with sporadic pres-
entations of extreme phenotypes of AOND were screened 
for known Mendelian genes and by WES, a large proportion 
remained genetically unexplained. The application of WGS 
may further expand the spectrum of causal DNMs by allow-
ing for a better coverage of the exome, the identification 
of non-coding DNMs as well as balanced and unbalanced 
structural variants [54]. In addition, the recent development 
of more sensitive and specific next-generation sequencing 
applications has allowed researchers to test an alternative 
hypothesis: highly penetrant post-zygotic DNMs might 
explain part of these sporadic presentations.
Somatic mutations in adult‑onset 
neurodegenerative disorders
The hypothesis that a genetic mutation present in only a 
proportion of the neuronal cells can cause a neurological 
disease has been formulated quite early in the history of 
AOND genetics [139, 180]. To date, most studies still focus 
on the analysis of germline mutations present in all cells 
by studying DNA isolated from a large proportion of blood 
cells. However, recent improvements in sequencing technol-
ogies have enabled the accurate identification of post-zygotic 
including late-somatic mutations present in subsets of cells 
or even in single cells [3]. In different neurodevelopmental 
disorders, evidence has been provided that post-zygotic or 
late-somatic mutations can cause disease using a combina-
tion of technologies on different tissues [70, 141]. Some of 
these mutations were detected in blood samples, indicat-
ing that they occurred early during development. One can 
assume that post-zygotic mutations, if detected in multiple 
tissues or with high allelic ratios in blood, might be present 
in a significant proportion of brain cells. Hence, the level 
of causality between germline and post-zygotic functional 
variants should be comparable. It is much more complex to 
detect brain-specific somatic mutations. Autopsy of certain 
AOND cases sometimes reveal widespread neuropatho-
logical lesions, which would be more in line with germline 
causes of disease. A focal onset of disease, as seen in some 
types of primary progressive aphasia in the FTLD spectrum, 
on the other hand, suggests a role for late-somatic mutations. 
Overall, in neurodegenerative disorders eventually affecting 
a large part of the brain, one could assume that the causative 
mutations must be present in a high proportion of brain cells 
(neurons and/or glial cells). However, most of the AOND 
share mechanisms called seeding and spreading. These fea-
tures, also referred to as Prion-like properties, are conferred 
by proteins that can transfer their pathogenic state into wild 
type, normally folded proteins (seeding) and then spread into 
the whole brain following neuronal connections (for review, 
see [126]. This phenomenon has been studied first for the 
Prion protein itself. However, such properties are now being 
characterized for Tau, Aβ, TDP-43, α-synuclein, or even the 
Huntingtin protein even if they are not associated with a 
spontaneous infectious propensity. Similar to an external 
focal injection of pathologic proteins in animal models, one 
can hypothesize that a small proportion of cells carrying a 
somatic variant resulting in the production of a pathogenic 
misfolded protein could be the source of a cerebral neuro-
degenerative disorder. Low-level mosaics should therefore 
also be considered.
Lessons from control brains and clues 
for the interpretation of somatic mutations in AOND
Recently, novel sequencing approaches provided critical 
knowledge on post-zygotic variation in healthy control tis-
sues. The human genome is clearly not stable throughout life 
and post-zygotic variants may occur in any cell at any time 
(Fig. 1b). Replicating cells are particularly prone to somatic 
mutations, with highly replicating tissues such as the skin or 
hematopoietic tissue showing the highest somatic mutation 
burdens. External factors may favor the occurrence of muta-
tions during the replication phase of the DNA, including 
mutagenic agents such as radiation or toxic agents. Aging 
seems to be the strongest risk factor influencing the accu-
mulation of somatic mutations during clonal hematopoiesis 
[2]. We summarize hereafter the main points that we con-
sider of high importance for the analysis and interpretation 
of somatic variants, following the study of normal and dis-
eased brains.
1. Post-mitotic neurons exhibit an unexpectedly high bur-
den of post-zygotic mutations. The use of single-cell 
genomic approaches including WGS in neurons from 
non-diseased brains unveiled an unsuspected amount of 
post-zygotic mutations, including about 1500 somatic 
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SNV per neuron [98]. Of them, some occurred dur-
ing fetal development [15, 75], but a higher burden 
was detected in post-mortem adults [98]. Although the 
number of single neurons that have been sequenced 
remains limited (dozens or hundreds), the elevated rate 
of post-zygotic SNV was quite unexpected as neurons 
are post-mitotic lifelong cells and hence are not sub-
jected to errors during DNA replication, beyond the ones 
putatively acquired during the divisions of progenitors. 
Single neuron somatic SNV were mostly associated with 
transcriptional activity, i.e., neuronal activity, contrary 
to the variants shared by multiple cells in the brain or 
tissues with a high replication rate [98]. In addition, 
neurons may accumulate late-somatic mutations dur-
ing aging [97]. Whatever the associated mechanisms, 
some of these events could result in the production of 
an abnormal/misfolded protein, which could represent 
a source of seeding and spreading in the brain, causing 
a neurodegenerative disease.
2. Bulk brain tissue is a combination of replicating and 
non-replicating, post-mitotic cells; sequencing genomic 
DNA isolated from bulk brain tissue does not allow the 
distinction between the cell types [64]. The identifica-
tion of very low-level mosaics from bulk brain tissue 
does not imply that different cell types carry the muta-
tion of interest and that the mutated genes are expressed 
in the mutated cells, hence leading to the production of 
an abnormal protein.
3. Although the access to brain tissue is mandatory to 
assess the somatic variant hypothesis thoroughly, study-
ing other tissues may be worth of interest. It has been 
shown that mutations present in more than 5–10% of 
the brain cells were generally also detected outside the 
brain, in tissues derived from all three embryonic layers, 
including the ectoderm, suggesting that these mutations 
occurred during early phases of embryonic development 
[98]. Although this still requires replication, this is a 
strong argument for assessing other tissues, including 
ectodermal tissues and blood, when cerebral tissue is 
not available. The fact that some neuronal cells shared 
more common cellular ancestors with cells from other 
organs than the brain in one individual was also a sur-
prising but promising finding for deep-sequencing stud-
ies performed on other tissues than the brain in AOND. 
However, every study performed from non-CNS tissue 
will be facing the non-representativeness of the allelic 
ratios eventually identified, and the lack of evidence 
that a putatively causal mutation with a low allelic ratio 
is really present in the affected neuronal cells. Impor-
tantly, recent results of single neuron WGS also raised 
the question of thresholds: if a putatively pathogenic 
mutation is found in a brain with an AOND, how many 
neurons should carry it, among the tens of billions of 
neurons in the brain [14], to be significant enough to 
cause a widespread neurodegenerative disease?
4. Data from mouse models suggest that seeds from periph-
eral tissues like blood [28] or intestine [82] can spread 
into the brain and cause a neurodegenerative disorder. 
The presence of a pathogenic mutation in the brain cells 
would hence not be mandatory to cause such a disease, 
although one can assume that a significant amount of 
pathological seeds should be produced to trigger an 
AOND.
5. The study of somatic aneuploidy and CNVs still requires 
technological improvements. Aneuploidy has been stud-
ied in AD brains for decades (for review see [9, 131, 
145, 146], mainly thanks to slice-based cytometry and 
fluorescent in situ hybridization (e.g., [10, 106, 146]). 
The fraction of neurons containing extra chromosomes 
has been reported to be higher in AD brains than in con-
trols [106]. Controversial results on aneuploidy rates 
ranging from 1% or less to more than 50% percent have 
been reported, as recently reviewed together with other 
inconsistencies (see [145, 146]). After the introduction 
of single cell NGS, the fraction of aneuploid neurons 
has been reevaluated to be from 0 to 3% [30, 80, 103, 
172] and the rate of neurons carrying post-zygotic CNVs 
has been evaluated to several dozen percents. Given the 
challenging assessment of germline CNVs using NGS 
in general, the interpretation of CNVs from single cell 
WGS may also require caution and improved techniques 
are required as proposed recently [144]. In addition, it 
has been shown that DNA isolation protocols may sig-
nificantly influence CNV detection [109]. Similar to 
CNVs, a high burden of post-zygotic L1 insertions that 
can disrupt or deregulate the expression of genes has 
been reported, although there are differences of opinions 
on the numbers of post-zygotic L1 insertions in single 
neurons [50, 171]; some results may require technical 
validation.
6. The study of brains from AOND cases implies the 
analysis of patients with advanced disease, which can 
be associated with secondary DNA damage. Increased 
aneuploidy rates and/or of DNA content in AD neuronal 
cells could be related to errors during mitosis of neu-
ronal progenitors. More likely, though, it can be caused 
by a reentry in the cell cycle as the result of AD patho-
physiological processes. This has been suggested by the 
identification of neurons with 4n DNA content and a 
positive staining for Cyclin B1 [106]. It is likely that, 
in the context of advanced neurotoxicity, such observa-
tion could basically be a simple consequence of neu-
rodegeneration—nonspecific to a given AOND instead 
of a causative mechanism [9]. In theory, the study of 
so-called preclinical AD brains could help tackle this 
issue. However, a proportion of neurons in preclini-
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cal AD brains might already be at a final stage of the 
pathophysiology. Studies of presymptomatic patients 
carrying APP, PSEN1, or PSEN2 mutations showed evi-
dence of neuronal damages years before the first clini-
cal signs, similar to what has been observed in animal 
models [21, 79, 131]. Even if a few studies had access to 
samples of patients with preclinical or early-stage AD, 
most research is performed on end-stage AD as it has 
been the main condition leading to the patient’s death. 
While many neurons already died, many other neurons 
have undergone stress and toxicity during years, before 
the first symptoms appeared. Some of them have accu-
mulated DNA damage, including somatic SNVs [97]. 
Oxidative stress and microtubule dysfunction in AD 
neurons are several of the causes leading to secondary 
damages in the DNA. In FTLD and ALS, it has been 
shown that secondary DNA damage can participate in 
the pathophysiological processes in C9ORF72 and FUS 
mutation carriers [51, 110]. Interpreting genetic results 
from AOND brains should therefore be done with great 
caution. Of note, similar caution should be provided for 
the interpretation of somatic mitochondrial DNA muta-
tions which face the same issue of possible secondary 
mutations induced by neurodegeneration. In addition, 
caution is required when interpreting negative findings 
in sequencing studies performed on brain tissue. Indeed, 
the mutated cells may also be the more vulnerable ones 
and hence mutations may be undetectable because of 
cellular death.
Taken together, somatic mutations in the brain may result 
from (1) early embryonic events, (2) mutations occurring in 
neuronal progenitors during neurodevelopment as a result 
of replication errors, (3) mutations in replicating cells in the 
brain at any stage of life as a result of replication errors, (4) 
mutations in post-mitotic neurons as a result of transcrip-
tional activity and (5) as a result of DNA damage in the 
context of cellular stress. Although advances in genomic 
and single cell technologies have provided novel information 
and promising hypotheses, the interpretation of sequencing 
data obtained from brains with AOND will be an even big-
ger challenge than the technology itself in the near future.
Somatic mutations in patients with AOND
Given the role of germline duplications of APP and SNCA, 
respectively, in autosomal-dominant EOAD and Parkin-
son’s disease, CNV studies have focused on these loci as 
well as chromosomal abnormalities. There is still debate on 
whether AD brains are enriched in neurons carrying extra 
copies of chromosome 21 containing the APP gene. Inter-
estingly, Bushman et al. [29] recently reported increased 
copy numbers of the APP locus itself in AD brains. So 
far, however, this exciting result has not been replicated. 
Even more recently, the study of nigral dopaminergic neu-
rons—the neurodegeneration of which causes Parkinson’s 
disease—revealed an average proportion of dopaminergic 
neurons with gains of SNCA copies in each nigra of 0.78% 
in Parkinson disease patients versus 0.45% in controls [105]. 
Such enrichment was not found in non-dopaminergic neu-
rons. Overall, among the 40 patients, 31 (77.5%) had at least 
one dopaminergic neuron showing a gain of SNCA copies 
as compared to 10/25 (40%) of the controls. These results 
suggest that late-somatic copy number gain of SNCA is not 
a rare event and suggest that a significant enrichment should 
be required to trigger the disease. The fact that picomolar 
concentrations of SNCA oligomers can induce disease-
related pathways in cells in vitro seems to be in paradox 
with the latter study [68]. If replicated, these results obtained 
on nigral neurons would question the hypothesis that low-
level mosaics alone would be sufficient to trigger diffuse 
neurodegenerative disease in vivo. Other brain regions may 
also be studied as well as other mutations and their putative 
functional consequences.
In addition to CNVs affecting known disease genes, 
post-zygotic CNVs may also affect novel Parkinson’s dis-
ease genes. In phenotypically discordant monozygotic twin 
pairs with one of the twins exhibiting Parkinson’s disease, 
a few post-zygotic novel CNVs have been identified in the 
affected twins [27]. Further research is needed to confidently 
link these genes to Parkinson’s disease.
The presence of brain-specific single nucleotide muta-
tions has been assessed in 1988—before the identification of 
the first causative genes of autosomal-dominant EOAD. In 
an exploratory study, the sequence encoding the Aβ peptide 
was analyzed in cDNA isolated from three brains with spo-
radic AD but no mutation was found [180]. The hypothesis 
that post-zygotic mutations could explain sporadic AD was 
reassessed after identification of APP, PSEN1, and PSEN2 
germline pathogenic mutations in autosomal-dominant fami-
lies. The analysis of DNA isolated from bulk brain pieces 
of 99 patients with sporadic AD revealed a PSEN1 mutation 
that was eventually confirmed to be present in the germline 
[139]. This hypothesis was also assessed in Parkinson’s dis-
ease and ALS before the era of NGS, with negative results 
[121, 135]. Recently, WES was performed in hundreds of 
brains from patients with different types of AOND. While 
pathogenic mutations were detected in autosomal-dominant 
genes, parental DNA was not available for testing and the 
average depth of sequence coverage did not allow for the 
detection of low-level somatic mutations [76].
The use of deep-sequencing or blood–brain duo strate-
gies has been applied only recently in sporadic AD. In a 
first study, a targeted deep-sequencing approach was used to 
analyze the genomic loci of APP, PSEN1, PSEN2 and MAPT 
in DNA isolated from the entorhinal cortex of 72 patients 
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with sporadic AD and 58 controls [152]. Custom capture and 
deep sequencing of the genomic regions of these four genes 
revealed 107 candidate post-zygotic mutations but only 3 
could be confirmed by amplicon-based deep sequencing: two 
novel MAPT missense mutations of unknown significance 
in sporadic AD patients (variant allele frequencies of 1.0% 
and 1.1%) and one known PSEN2 likely benign missense 
mutation (variant allele frequency of 1.6–5.7%) in a con-
trol. Of note, among the 41 patients with an available age at 
onset, the median age of onset was 78 years (range: 46–92) 
and among the other 31 other patients, the median age at 
death was 79 years (range 57–96, the youngest carried a 
pathogenic PSEN1 germline variant p.H163R), suggesting 
that majority had a late disease onset. Another recent study 
focused on more technical aspects in the context of AD, but 
did not provide results directly relevant to AD itself [57]. In 
a study including 17 sporadic AD patients, 2 controls, and 2 
patients with vascular dementia, WES (mean depth of cover-
age: 60.8x) was performed on DNA isolated from blood as 
well as the hippocampus [122]. This strategy did not allow 
the identification of low-level mosaics and no putatively 
pathogenic brain-specific mutation was identified. The aver-
age age at death was 86.8 years (range 73–94), suggesting 
that most of them, if not all, presented a late onset of AD.
With the hypothesis that, similar to germline DNM, 
post-zygotic, including late-somatic mutations causing spo-
radic AOND may be associated with early-onset forms, we 
recently performed a targeted deep-sequencing screen of 11 
genes in 445 sporadic AD patients (355 blood samples, 100 
brain samples), > 80% of which had an early onset [112]. We 
used single molecule Molecular Inversion Probes (smMIPs) 
capture followed by deep sequencing and validation with 
independent ultra-deep sequencing, allowing for very high 
sensitivity and specificity. We identified nine post-zygotic 
mutations with allelic ratios ranging from 0.2% to 10.8%. 
Two of these mutations were predicted to alter the func-
tion of SORL1, which is currently considered as a strong 
risk factor for EOAD. However, no predicted pathogenic 
post-zygotic mutations in known autosomal-dominant genes 
could be identified in this large sample.
Even more recently, 102 genes were screened by targeted 
capture followed by deep sequencing in 173 samples from 54 
human brains [75]. Post-zygotic variants were validated by a 
technology including the use of UMI. Of them, 20 individu-
als presented with AD and 20 exhibited Parkinson’s disease 
or dementia with Lewy bodies. Despite the detection of 62 
post-zygotic variants, no putatively pathogenic variant was 
identified.
The preliminary results of the above-mentioned stud-
ies do not immediately point to a significant role for post-
zygotic mutations in known disease genes sporadic AOND. 
This may change with improvements in capture as well as 
sequencing technologies (including the analysis of single 
cells which is only just starting and is a tremendously prom-
ising field) as well as the analysis of many more brain sam-
ples, especially from patients with an early onset of disease 
and the more accurate detection of mosaic structural vari-
ations. Taking together all the positive and negative results 
obtained from control and diseased brains, the assessment of 
the somatic variant hypothesis in AOND has opened many 
novel questions. Among them, there is discussion about the 
minimum amount of pathological seeds, the timing of occur-
rence, and the regions where these seeds should appear to be 
sufficient to trigger neurodegenerative diseases. Experiments 
in animal models may help researchers to answer some of 
these questions, combined with the application of ultra-
sensitive sequencing of multiple brain regions in AOND 
patients and controls.
Conclusions
Pathogenic DNMs, while not easy to identify in adult-onset 
diseases, clearly play an important role in sporadic AOND. 
Trio-based exome sequencing of patient–parent blood sam-
ples has pointed to numerous germline DNMs in both known 
disease genes as well as novel candidate genes. Larger sam-
ple sizes and functional follow-up studies are essential to 
validate the role of these candidate genes in AOND. Access 
to affected brain tissue and more sensitive and specific 
sequencing approaches will be crucial to investigate further 
the role of brain-specific mutations in AOND. Challenges 
lie ahead not only in the identification of these mutations but 
equally in the clinical interpretation of mutations that are 
present in only a proportion of all cells present.
In this review, we focused on the most common AOND, 
but examples of germline or post-zygotic DNM in known 
Mendelian genes causing other adult-onset neurological dis-
orders have been reported (e.g., [46, 49, 115, 159]).
The in-depth genomic analysis of sporadic AOND is 
opening many exciting novel research directions, from the 
identification and characterization of novel disease genes 
and non-coding regions to the single cell analysis of somatic 
mutations as well as the analysis of seeding-spreading mech-
anisms leading to neurodegenerative disorders.
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Box 1. Overview of the most common 
adult‑onset neurodegenerative disorders 
and genetics aspects in Mendelian forms
Mendelian inheritance corresponds to monogenic disorders, 
where, in a given individual, mutations in a single gene 
(whatever its type, single nucleotide change, copy number 
variation, causing disease in a dominant or recessive man-
ner) are sufficient to cause disease. In most AONDs, it is 
expected that monogenic forms represent a small minor-
ity of all patients, with an enrichment of monogenic forms 
observed in the more severe and earlier-onset forms. Because 
of the adult onset of these disorders, mutations can be passed 
on to the offspring and therefore monogenic AOND can 
occur in families. In addition, although monogenic Prion 
disorders are genetically homogeneous (same gene affected 
in every patient: PRNP), monogenic forms of Alzheimer’s 
disease, frontotemporal lobar degeneration, amyotrophic lat-
eral sclerosis and Parkinson’s disease are genetically hetero-
geneous: a single mutation in a given gene may be sufficient 
to cause disease in a given patient, but different genes are 
mutated in different patients.
Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia. 
It is characterized by a progressive decline of memory and 
other cognitive functions related to the spreading of neuronal 
lesions called neurofibrillary tangles which are mainly com-
posed of hyper- and abnormally phosphorylated Tau protein. 
These lesions are however not specific to AD. The other 
mandatory neuropathologic criterion, which is specific to 
AD, is the presence of senile plaques, the core of which is 
composed of aggregated Aβ peptide.
AD is a complex disorder in the vast majority of cases. 
It is commonly postulated that less than 1% of the patients 
exhibit an autosomal-dominant form, but this may be actu-
ally much less. Three genes have been validated as causing 
autosomal-dominant AD when carrying pathogenic vari-
ants: APP, PSEN1, and PSEN2 [36, 143, 160, 161]. APP 
encodes the precursor of the Aβ peptide, which results from 
the sequential cleavage of APP by the β-secretase and the 
γ-secretase (PSEN1 or PSEN2 encoding the catalytic subu-
nits). Pathogenic variants are responsible for the increased 
production of the Aβ peptide or the production of a more 
aggregation-prone form. Majority of the pathogenic variants 
are highly penetrant and result in a disease onset before the 
age of 65 years (for review, see [113]). Mutation detection 
rates highly correlate with the combination of ages of onset 
and family history (Fig. 2).
Frontotemporal lobar degeneration (FTLD) 
spectrum
Frontotemporal lobar degeneration (FTLD) is a neurode-
generative disorder affecting mainly the frontal and tempo-
ral lobes. It is the second most common cause of dementia 
before the age of 65, after Alzheimer’s disease [118]. It is 
characterized by a clinical heterogeneity which is classi-
fied into different syndromes. Behavioral frontotemporal 
dementia (bvFTD) is the most common clinical syndrome. 
Patients exhibit progressive deterioration of personality, 
social behavior, and cognitive impairment [138]. Other 
patients may exhibit a primary language impairment and 
fulfill the criteria of primary progressive aphasia, itself 
divided into subtypes. FTLD is better classified based on 
neuropathologic findings. FTLD-Tau is characterized by 
neuronal inclusions of the Tau protein. The other subtypes 
show immunomarquages negative for Tau and positive for 
ubiquitin. Among the latter ones, the FTLD-TDP subtype is 
characterized by inclusions of the TDP-43 protein, while the 
FTLD-FET is positive for the FET family of proteins includ-
ing the FUS protein. FTLD itself belongs to a spectrum of 
diseases with amyotrophic lateral sclerosis (ALS) being the 
main co-occurring phenotype. ALS is a devastating neu-
rodegenerative disorder affecting the primary and second-
ary motor neurons and typically leading to death 3–5 years 
following the diagnosis [168]. Some of the patients exhibit 
ALS, FTLD, or both. Additional phenotypes can also be 
encountered.
Most of the Mendelian forms of this spectrum are trans-
mitted as an autosomal-dominant trait. Pathogenic variants 
in the MAPT gene encoding the Tau protein cause FTLD-Tau 
with or without parkinsonism or a related disorder called 
progressive supranuclear palsy. FTLD-TDP can be caused by 
rare mutations in TARDBP encoding TDP-43 itself (however 
mainly causing ALS), but it is more commonly associated 
with hexanucleotide expansions in a non-coding region of 
C9ORF72 or protein-truncating variants in GRN (for review, 
see [133]). Mutations in VCP, HNRNPA1 and HNRNPA2B1 
cause an even larger group of disorders adding Paget disease 
of bone and inclusion body myopathy to the FTLD–ALS 
spectrum. Mutations in FUS have been reported in families 
with ALS. SOD1 mutations cause a specific subtype of ALS 
without FTLD. Other genes have been identified and account 
for a smaller proportion of patients, each (for review, see 
[133]).
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In the FTLD spectrum, physicians face the difficulty to 
select patients for genetic screening. Although younger cases 
and multiplex families are easily recognized as good candi-
dates for genetic studies, there is no clear age or family his-
tory-related criteria to help clinicians decide. Different neu-
rodegenerative disorders must be taken into account when 
considering the presence or absence of a family history. Up 
to 43% of the FTLD patients presented a first-degree rela-
tive with dementia, ALS, or Parkinson’s disease [133]. The 
reduced penetrance of several mutations including the most 
common ones (C9ORF72, GRN) [108] has led some authors 
to propose genetic analysis to all patients with a phenotype 
belonging to this spectrum [11, 17, 170]. Given this incom-
plete penetrance, it is not surprising to find reports of spo-
radic cases carrying a pathogenic mutation, however, the 
absence of parental DNA often precluded the assessment of 
their inheritance (e.g., GRN [90], MAPT [142]).
Prion disorders
Prion diseases are a group of neurodegenerative disorders 
related to the misfolding of the Prion protein encoded by the 
PRNP gene. They are usually classified as familial, “spo-
radic” or transmissible. The familial forms (~ 15% of the 
cases) actually mean autosomal dominant and are related to 
pathogenic mutations in the PRNP gene. It is postulated that 
autosomal-dominant Prion disease is genetically homogene-
ous, i.e., all cases should carry a pathogenic PRNP muta-
tion. The term sporadic is often used to characterize complex 
forms (all non-autosomal dominant and non-transmissible 
situations) whatever the presence or absence of any family 
history. Here we use the term “complex” instead of sporadic 
and keep “sporadic” for designating patients with a nega-
tive family history. The acquired (or transmissible) forms 
represent a small minority of the cases. Three main clini-
cal syndromes have been described to be associated with 
PRNP pathogenic mutations: Creutzfeldt–Jakob disease 
(CJD), Gerstmann–Sträussler–Scheinker (GSS) syndrome, 
and fatal familial insomnia (FFI).
Parkinson’s disease, synucleinopathies
Alpha-synucleinopathies regroup different neurodegen-
erative disorders characterized by the aggregation of the 
α-synuclein protein in the so-called Lewy bodies in the 
brains. Parkinson’s disease (PD) is a common complex dis-
order. The typical clinical presentation is an extrapyramidal 
syndrome characterized by L-Dopa responsive asymmetric 
resting tremor, akinesia, and rigidity. Additional neuro-
logical manifestations and atypical disease courses can be 
observed and some patients might exhibit dementia in the 
late stages of the disease. The clinical evolution is thought 
to be related to the spreading of neuronal lesions from the 
substantia nigra to other brain areas including the cortex. A 
minority of the patients present a Mendelian form, either 
with an autosomal-dominant transmission such as for SNCA, 
the gene-encoding α-synuclein itself, LRRK2, or VPS35 
genes, or with an autosomal recessive transmission such 
as for PARK2 (Parkin), PARK7 (DJ-1), or PINK1 genes, 
amongst others (for review, see [62]). Dementia with Lewy 
bodies (LBD) is the second most common neurodegenera-
tive cause of dementia in the elderly after AD. It shares 
clinical and pathological features with Parkinson’s and Alz-
heimer’s diseases and is associated with widespread Lewy 
bodies in the brain including cortical areas. There is little 
evidence of families with an autosomal-dominant transmis-
sion. Mutations in genes known to cause Mendelian forms of 
other AOND have been identified in LBD patients, including 
mutations or triplications of SNCA. However, little is still 
known about LBD genetics (for review, see [176]) and the 
co-existence of Lewy bodies with AD pathology in some 
patients can be confusing, including some cases with patho-
genic mutations in AD genes (APP duplications, PSEN1/2 
variants [59, 74, 176]).
Multiple system atrophy (MSA) is  another 
α-synucleinopathy. The main clinical characteristics include 
an extrapyramidal syndrome, a cerebellar syndrome, and 
autonomic dysfunction. In MSA, the α-synuclein protein 
aggregates primarily in oligodendrocytes, forming glial 
cytoplasmic inclusions. The genetics of MSA are debated. It 
is postulated that it is a common complex disorder. Recently, 
bi-allelic mutations in the COQ2 gene have been identified 
in multiplex families with MSA, but the role of this gene is 
debated due to negative replication studies [72, 104, 107, 
119, 137, 156, 158]. There is no evidence of autosomal-
dominant MSA and of DNM in this disorder to date (for 
review see [89]).
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